Tris Promethazine and Codeine Syrup: Complete Prescribing Guide

Tris Promethazine and Codeine Syrup is a prescription Schedule V medication manufactured by Tris Pharma, Inc. that combines promethazine hydrochloride and codeine phosphate to treat selected severe, non-productive coughs. Because it contains an opioid, it carries FDA Boxed Warnings for addiction, respiratory depression, and dangerous drug interactions.

Tris Promethazine and Codeine Syrup is a prescription-only Schedule V controlled substance manufactured by Tris Pharma, Inc. It combines promethazine hydrochloride and codeine phosphate to temporarily relieve certain severe, non-productive coughs in appropriately selected patients. Because it contains an opioid, it carries FDA Boxed Warnings for addiction, respiratory depression, and potentially fatal drug interactions.

Tris Promethazine and Codeine Syrup is a clinically regulated prescription medication manufactured by Tris Pharma, Inc., combining promethazine hydrochloride — a first-generation phenothiazine antihistamine — with codeine phosphate, an opioid antitussive. Classified as a DEA Schedule V controlled substance, it is indicated for the short-term management of selected severe, non-productive coughs when clinical benefits demonstrably outweigh patient-specific risks. The FDA has issued Boxed Warnings for addiction, misuse, life-threatening respiratory depression, and additive central nervous system depression from alcohol and other CNS depressants. Appropriate use requires precise weight- and age-based dosing, pharmacogenetic awareness of CYP2D6 metabolizer status, and direct oversight by a licensed healthcare professional.

What Is Tris Promethazine and Codeine Syrup?

Tris Promethazine and Codeine Syrup is a combination prescription medication developed to address certain severe, non-productive coughs and associated upper respiratory symptoms. Manufactured by Tris Pharma, Inc., the formulation pairs two pharmacologically distinct agents: promethazine hydrochloride, a sedating first-generation antihistamine classified within the phenothiazine family, and codeine phosphate, an opioid cough suppressant that acts centrally on mu-opioid receptors in the brainstem cough center.

Because it contains codeine — a federally controlled opioid — the medication is classified as a DEA Schedule V controlled substance and is legally available only with a valid prescription from a licensed healthcare provider. The FDA has issued formal Boxed Warnings, its highest-tier safety designation, to alert prescribers and patients to serious risks including opioid addiction, misuse, life-threatening respiratory depression, and dangerous interactions with alcohol and central nervous system depressants.

This guide provides a clinically grounded overview of Tris promethazine and codeine ingredients, dosage parameters, contraindications, drug interactions, and comparative context against generic alternatives. It is structured as an informational reference only and does not substitute for individualized medical advice from a qualified healthcare professional.

Tris Promethazine and Codeine Syrup Ingredients: What’s Inside the Bottle

Understanding the active and inactive composition of Tris Promethazine and Codeine Syrup is foundational to evaluating its therapeutic potential and risk profile.

Active Ingredients (per 5 mL standard dose)

Promethazine hydrochloride exerts its primary effects through antagonism of H1 histamine receptors, producing antihistaminic, sedative, antiemetic, and mild anticholinergic activity. In the context of cough management, its sedative properties complement codeine’s central antitussive action, though this combination also substantially increases CNS depression risk.

Codeine phosphate is a prodrug that undergoes hepatic metabolism to morphine via the CYP2D6 enzyme. It suppresses cough by directly depressing the brainstem cough center through mu-opioid receptor agonism. This metabolic pathway carries significant clinical implications: patients identified as CYP2D6 ultra-rapid metabolizers convert codeine to morphine at accelerated rates, substantially elevating opioid toxicity risk even at standard prescribed doses.

Inactive Ingredients

The inactive components of Tris Promethazine and Codeine Syrup may include flavoring agents, preservatives, colorants, and stabilizers. These excipients do not contribute to the drug’s therapeutic action but may be clinically relevant for patients with documented allergies or sensitivities to specific dyes, sulfites, or flavoring compounds. Prescribers and pharmacists should review the complete inactive ingredient list for vulnerable populations, including those with known phenol or sulfite sensitivities.

Always verify the current inactive ingredient list through the dispensing pharmacist or the official DailyMed prescribing information database maintained by the National Library of Medicine.

What Is Tris Cough Syrup Used For?

Tris Promethazine and Codeine Syrup is prescribed for the short-term relief of selected severe, non-productive coughs associated with upper respiratory illnesses when the expected clinical benefits outweigh the risks of opioid therapy. It carries a narrow, clinically defined therapeutic indication and is not appropriate for routine cough suppression or mild upper respiratory symptoms.

FDA-Approved Indication

The medication is approved for the temporary relief of certain severe, non-productive (dry) coughs in patients for whom the clinical benefit of cough suppression clearly outweighs the inherent risks of opioid therapy. Promethazine’s antihistaminic properties may provide additional benefit for associated upper respiratory symptoms such as nasal congestion and mild allergic rhinitis.

Conditions Where It May Be Prescribed

• Severe non-productive cough associated with upper respiratory infections
• Post-infectious dry cough causing significant functional impairment
• Cough complicated by concurrent allergic respiratory symptoms

When It Is Not Appropriate

Tris Promethazine and Codeine Syrup is not appropriate for:

• Productive coughs that assist in airway clearance
• Pediatric patients under 12 years of age
• Postoperative pain management in pediatric tonsillectomy or adenoidectomy patients
• Patients in whom opioid therapy is contraindicated
• Routine or mild cough associated with the common cold in otherwise low-risk adults

Clinical Perspective: Cough is a physiological defense mechanism. Suppressing a productive cough may impair mucociliary clearance and prolong lower respiratory infections. Codeine-based antitussives are most defensible when the cough is non-productive, severe, and causing clinically meaningful distress — not as a first-line intervention for every respiratory illness.

Clinical Decision Framework: Is This Medication Appropriate?

The following framework reflects standard clinical reasoning for evaluating promethazine with codeine candidacy. It is not a substitute for individualized prescriber judgment.

Severe cough present?
        ↓
Is the cough non-productive (dry)?
        ↓
Have safer first-line alternatives been considered?
        ↓
Is the patient aged 12 or older?
        ↓
Are there contraindications (asthma, respiratory depression,
MAOI use, opioid hypersensitivity)?
        ↓
Does the patient have documented substance use disorder history?
        ↓
Have all interacting medications been identified and reviewed?
        ↓
If benefits outweigh risks → Prescribe with Boxed Warning counseling,
minimum quantity, and defined treatment duration

If any exclusionary criterion is present, alternative antitussive therapy or diagnostic workup for the underlying cause of cough is indicated before considering opioid-containing medications.

Promethazine with Codeine Purple Syrup: The Street Name Problem

Promethazine with codeine — including formulations such as Tris Promethazine and Codeine Syrup — is widely recognized in illicit drug culture under the street names “lean,” “purple drank,” or “sizzurp.” This terminology derives from the characteristic purple or deep violet color produced by certain dyes included in some commercial formulations.

This cultural context represents a critical and ongoing public health concern. The recreational use of promethazine with codeine purple syrup — frequently combined with alcohol, benzodiazepines, or other opioids to amplify CNS depression — has been directly associated with fatal respiratory depression, opioid overdose deaths, and addiction, particularly among adolescents and young adults. The Centers for Disease Control and Prevention and the National Library of Medicine have documented this pattern extensively in peer-reviewed literature and public health surveillance data.

According to the CDC’s opioid overdose surveillance data (2024), opioid-involved deaths continue to disproportionately affect young adults, with codeine-containing formulations contributing to a subset of cases involving polydrug combinations. This misuse profile is a primary driver of the FDA’s Boxed Warning requirements, the DEA’s Schedule V classification, and increasingly stringent prescribing oversight protocols at both federal and state levels.

Tris Promethazine Codeine Side Effects

All patients receiving Tris Promethazine and Codeine Syrup should receive comprehensive counseling on both expected and potentially life-threatening adverse effects before initiating therapy.

Common Side Effects

These effects occur at therapeutic doses and directly reflect the pharmacological properties of both active ingredients:

• Drowsiness and sedation — Most frequent; attributable primarily to promethazine’s CNS-depressant properties
• Dizziness and impaired coordination
• Dry mouth — Anticholinergic effect of promethazine
• Constipation — Opioid-mediated gastrointestinal motility reduction
• Blurred vision
• Nausea and vomiting
• Urinary retention

Patients must be specifically counseled not to operate motor vehicles, heavy machinery, or perform tasks requiring sustained cognitive attention until the full sedative effect of the medication is individually characterized.

Serious and Life-Threatening Side Effects

The following adverse effects require immediate emergency medical evaluation — call 911 without delay:

Clinical Warning: Neuroleptic Malignant Syndrome (NMS) is a rare but potentially fatal reaction associated with phenothiazine-class drugs, including promethazine. It presents as a constellation of hyperthermia, generalized muscle rigidity, altered consciousness, and autonomic instability. Any clinician observing this presentation in a patient receiving promethazine-containing medications should discontinue the drug immediately and initiate emergency management. Early recognition is the primary determinant of survival.

Long-Term Use Considerations

Extended use beyond prescribed short-term intervals carries escalating and compounding risks:

• Physical dependence on codeine, even within prescribed dose ranges over time
• Opioid tolerance, requiring progressively higher doses for equivalent therapeutic effect
• Psychological addiction in genetically and contextually susceptible individuals
• Chronic constipation and associated gastrointestinal complications including obstipation
• Persistent cognitive effects from sustained CNS depression

Tris Promethazine and Codeine Syrup is not indicated for chronic cough management. Persistent cough beyond the expected resolution of an acute illness warrants formal diagnostic evaluation — not ongoing antitussive therapy.

Can Patients Drive While Taking Tris Promethazine and Codeine Syrup?

No. Patients should not drive, operate heavy machinery, or engage in any safety-sensitive activity while taking Tris Promethazine and Codeine Syrup.

Promethazine produces substantial CNS sedation that may persist for up to 12 hours following a single dose — well beyond the 4-to-6-hour antitussive window of codeine. This sedation impairs reaction time, motor coordination, and decision-making capacity at levels comparable to legal alcohol impairment. Codeine independently contributes to cognitive slowing and reduced psychomotor performance.

The combination creates a level of functional impairment that is clinically incompatible with the safe operation of any motorized vehicle or equipment. Patients should be counseled explicitly on this restriction at the point of prescribing and dispensing, and caregivers should be advised when the patient’s age or condition warrants additional oversight.

Tris Prescription Cough Syrup Dosage

Dosing for Tris Promethazine and Codeine Syrup is individualized based on patient age, body weight, renal and hepatic function, concurrent medications, and overall clinical risk profile. The following parameters represent standard prescribing reference points, not personalized therapeutic recommendations.

Adult Dosage (Age 18 and Older)

• Standard dose: 5 mL orally every 4 to 6 hours as needed
• Maximum daily dose: Do not exceed 30 mL in any 24-hour period
• Administration: Oral, with or without food

Adolescent Dosage (Ages 12 to 17)

• Standard dose: 2.5 mL to 5 mL orally every 4 to 6 hours as needed
• Maximum daily dose: Do not exceed 30 mL in 24 hours
• Prescribing in this age group requires careful, individualized risk-benefit determination and documented clinical justification

Pediatric Use (Under Age 12)

Absolutely contraindicated. The FDA has determined that children under 12 years face an unacceptable risk of life-threatening respiratory depression from codeine, particularly those with CYP2D6 ultra-rapid metabolizer genotypes. This contraindication is absolute and without clinical exception.

Can Tris Promethazine and Codeine Syrup Be Taken With Food?

Yes. Tris Promethazine and Codeine Syrup may be taken with or without food. Administering the dose with food or a full glass of water may reduce the likelihood of nausea in sensitive individuals. Food does not meaningfully alter the rate or extent of drug absorption for either active ingredient at standard therapeutic doses.

Missed Dose

If a scheduled dose is missed, take it as soon as remembered — unless the next scheduled dose is approaching, in which case the missed dose should be skipped entirely. Do not double the dose to compensate for a missed one. Doubling doses of codeine-containing medications substantially increases the risk of CNS and respiratory depression.

Dosing Considerations for Special Populations

• Elderly patients: Increased susceptibility to sedation, falls, respiratory depression, and anticholinergic effects such as urinary retention and confusion. Begin at the lowest effective dose and titrate cautiously.
• Renal or hepatic impairment: Both codeine and promethazine undergo hepatic metabolism and renal excretion. Dose adjustment or selection of alternative therapy should be carefully considered in these populations.
• CYP2D6 ultra-rapid metabolizers: These patients convert codeine to morphine at rates significantly exceeding population norms, creating disproportionate opioid exposure at standard therapeutic doses. The National Library of Medicine’s PharmGKB database estimates that CYP2D6 ultra-rapid metabolizer prevalence ranges from 1% to 29% depending on ethnic ancestry. Pharmacogenetic screening may be clinically appropriate in high-risk clinical scenarios.

Safe Measurement

Always measure doses using a calibrated oral dosing syringe or medication cup specifically designed for liquid medications — never a household teaspoon. Household spoons vary in volume by 20% to 30%, introducing clinically significant dose variability and meaningful overdose risk, particularly in adolescent patients or those at the upper limit of the standard dosing range.

How Long Does Tris Promethazine and Codeine Last?

Most patients experience symptom relief within 15 to 30 minutes of oral administration. Cough suppression generally lasts 4 to 6 hours, while sedative effects from promethazine may continue for up to 12 hours depending on age, metabolism, and concurrent medications.

Duration of Effect

Clinical Note: Promethazine’s sedative duration routinely exceeds codeine’s antitussive duration. This pharmacokinetic mismatch means patients may experience persistent sedation well after cough relief has diminished. Patients and caregivers must account for this extended sedation window when evaluating fitness to drive, return to work, or supervise dependents.

Factors That Influence Duration

The effective duration of action varies based on:

• CYP2D6 genotype: Ultra-rapid metabolizers experience shorter but more intense opioid effects; poor metabolizers experience prolonged but attenuated responses
• Age: Elderly patients typically exhibit prolonged drug half-lives due to reduced hepatic and renal clearance capacity
• Concurrent medications: CYP2D6 and CYP3A4 inhibitors extend drug activity; inducers shorten it
• Hepatic and renal function: Impairment in either organ system prolongs drug accumulation and extends effect duration

Tris Promethazine Codeine Interactions

Drug interactions with Tris Promethazine and Codeine Syrup range from clinically significant to potentially fatal. Comprehensive medication reconciliation — including prescription drugs, over-the-counter medications, herbal supplements, and alcohol — is mandatory before initiating therapy.

Critical Interactions: Contraindicated or Requiring Extreme Caution

Central Nervous System Depressants

Co-administration with any CNS depressant produces additive or synergistic depression of brainstem respiratory control. This interaction mechanism underlies the majority of codeine-related overdose fatalities in polydrug contexts.

FDA Black Box Warning (Updated 2025): Concomitant use of opioids with benzodiazepines or other CNS depressants substantially elevates the risk of respiratory depression, coma, and death. Reserve concurrent prescribing for patients for whom no adequate therapeutic alternative exists, and limit both doses and treatment duration to the clinically necessary minimum.

Pharmacokinetic Interactions: CYP2D6 and CYP3A4

Codeine is a primary CYP2D6 substrate; promethazine is metabolized through multiple hepatic cytochrome pathways. Medications that inhibit or induce these enzymes directly and meaningfully alter drug exposure and clinical effect:

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion, quinidine): Reduce conversion of codeine to its active morphine metabolite, potentially diminishing therapeutic efficacy while altering the adverse effect profile in unpredictable ways
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): May increase plasma concentrations of promethazine and codeine metabolites, intensifying and prolonging CNS depression
• CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s Wort): May reduce drug concentrations below therapeutic thresholds, diminishing clinical efficacy

MAO Inhibitors (MAOIs)

Combining promethazine with MAOIs creates risk of serious, potentially fatal adverse reactions including hyperpyrexia, severe cardiovascular instability, and seizures. This combination is absolutely contraindicated. A minimum washout period of 14 days following MAOI discontinuation is required before initiating any promethazine-containing therapy.

Anticholinergic Medications

Promethazine’s inherent anticholinergic activity is additive with other anticholinergic agents, amplifying risk of urinary retention, severe constipation, paralytic ileus, blurred vision, and — particularly in elderly patients — acute anticholinergic delirium.

Alcohol: Mandatory Patient Counseling

Alcohol warrants unequivocal, explicit patient instruction: even moderate alcohol consumption concurrent with Tris Promethazine and Codeine Syrup can precipitate life-threatening respiratory depression. No safe threshold exists for alcohol use with this medication. Patients must be counseled to avoid all alcohol-containing products — including over-the-counter preparations, mouthwashes, and herbal tonics containing ethanol — throughout the complete treatment course.

Can Tris Promethazine and Codeine Syrup Cause a False Positive Drug Test?

Yes, this is a documented and clinically important consideration. Codeine is metabolized to morphine and may produce a positive urine immunoassay result for opioids. Patients who are subject to workplace drug testing, forensic screening, or clinical drug monitoring should proactively disclose their legitimate prescription to the testing administrator before providing a sample. Confirmatory testing using gas chromatography-mass spectrometry (GC-MS) can differentiate prescribed codeine metabolites from illicit opioid use when necessary.

Promethazine Codeine Schedule V: Controlled Substance Classification

Tris Promethazine and Codeine Syrup is federally classified as a DEA Schedule V controlled substance under the Controlled Substances Act.

What Schedule V Means

DEA Schedule V designates substances that have:

• Accepted medical use in the United States with established therapeutic applications
• Lower potential for abuse relative to Schedule I through IV substances
• Some potential for dependence, which remains a well-documented clinical reality despite the comparatively lower scheduling tier

Schedule V does not mean low-risk. Codeine dependence, addiction, and overdose occur within Schedule V prescribing contexts with documented frequency. The classification reflects the drug’s relative position within a scheduling hierarchy — not the absence of clinically meaningful harm potential.

Legal and Prescribing Implications

• A valid prescription from a DEA-registered, licensed practitioner is legally required in all U.S. jurisdictions
• State regulations frequently impose additional dispensing restrictions, quantity limits, and monitoring requirements beyond minimum federal Schedule V standards
• Prescribers are subject to DEA registration requirements and applicable state controlled substance prescribing laws
• Dispensing records are maintained in state Prescription Drug Monitoring Programs (PDMPs) and are subject to regulatory review

Tris Pharma Cough Syrup Bottle Sizes

Tris Pharma, Inc. distributes promethazine and codeine syrup in standardized pharmaceutical bottle sizes designed to align with responsible short-term prescribing quantities.

Common Bottle Sizes

Exact available sizes may vary by pharmacy, regional distributor, and current supply chain conditions. Confirm current availability directly with the dispensing pharmacist.

Prescribing Quantity and Diversion Risk

Responsible controlled substance prescribing practice supports dispensing the minimum effective quantity sufficient to treat the identified acute clinical episode. Excess medication volume increases household diversion risk — a well-documented pathway through which prescription opioids enter illicit channels. Patients should receive explicit counseling on secure, locked storage and the importance of proper disposal of unused medication through DEA-authorized drug take-back programs or FDA-recommended disposal methods.

Tris Promethazine Codeine vs. Generic: Clinical Equivalence and Practical Differences

Regulatory Framework

Generic promethazine with codeine oral syrup products approved by the FDA must demonstrate bioequivalence to the reference listed drug — meaning their rate and extent of absorption fall within FDA-defined equivalence boundaries under standardized pharmacokinetic testing conditions. This standard ensures that approved generics deliver pharmacologically equivalent active ingredient exposure to the branded reference product.

Active Ingredient Identity

All FDA-approved generic formulations of promethazine with codeine syrup contain identical active ingredients at identical strengths: 6.25 mg promethazine hydrochloride and 10 mg codeine phosphate per 5 mL. There is no clinically meaningful difference in pharmacological activity, therapeutic efficacy, or safety profile between bioequivalent formulations.

Where Differences Exist

Inactive ingredient differences — including colorants, flavoring agents, preservatives, and stabilizers — are clinically irrelevant for the vast majority of patients but warrant consideration for individuals with documented allergies to specific excipients such as sulfites, parabens, or artificial dyes.

Formulary Consideration: Generic formulations are typically substantially less expensive and are preferred under most insurance formularies. From a therapeutic standpoint, any FDA-approved bioequivalent generic is clinically interchangeable with the Tris-branded product for patients without relevant excipient sensitivities.

Tris Promethazine with Codeine vs. Promethazine DM: Key Differences

A clinically important and frequently searched comparison involves Tris Promethazine with Codeine versus Promethazine DM — a formulation that substitutes dextromethorphan (DM) for codeine phosphate.

Side-by-Side Comparison

Clinical Perspective: Promethazine DM is generally considered the lower-risk alternative for patients who require an antihistamine-antitussive combination but for whom opioid therapy is not clinically justified. However, dextromethorphan is not without its own misuse profile — at high doses, it produces dissociative psychoactive effects and is subject to recreational abuse, particularly among adolescents. Neither formulation should be treated as benign.

Tris Promethazine with Codeine vs. Benzonatate

Benzonatate (Tessalon Perles) is a non-opioid antitussive that represents a commonly prescribed alternative for severe, non-productive cough when opioid-based therapy is not clinically appropriate.

Comparison

Clinical Note: Benzonatate carries its own serious safety warnings. Swallowing broken or chewed capsules releases the drug rapidly, producing oropharyngeal anesthesia that can cause choking, laryngospasm, and cardiovascular collapse. Pediatric fatalities from accidental benzonatate ingestion are documented in the FDA adverse event reporting system. Neither antitussive class is without meaningful risk — the choice between them requires individualized clinical assessment.

Pregnancy, Breastfeeding, and Reproductive Safety

Pregnancy

Tris Promethazine and Codeine Syrup should be avoided during pregnancy whenever clinically possible. Codeine is classified under FDA’s updated prescribing framework as a medication with known fetal risk. Prolonged opioid use during pregnancy is a recognized cause of Neonatal Opioid Withdrawal Syndrome (NOWS), a condition requiring specialized neonatal monitoring and management. Promethazine crosses the placenta and may produce neonatal CNS and respiratory effects following delivery.

If cough management during pregnancy is clinically necessary, non-opioid alternatives should be exhausted before considering codeine-containing therapy. Any use during pregnancy requires explicit risk-benefit discussion and close obstetric oversight.

Breastfeeding

This medication is contraindicated during breastfeeding. Both codeine and its active morphine metabolite are excreted in human breast milk. In nursing infants — particularly those who may inherit CYP2D6 ultra-rapid metabolizer genotype from a breastfeeding mother — even small quantities of morphine transferred through breast milk can cause life-threatening respiratory depression. Infant deaths linked to codeine exposure through breast milk are documented in the FDA’s adverse event database and in peer-reviewed literature indexed by the National Library of Medicine.

The FDA specifically advises that codeine should not be used by breastfeeding mothers.

FDA Boxed Warnings: What Every Patient Must Know

The FDA’s Boxed Warning — the most prominent safety communication tool in U.S. pharmaceutical labeling — appears on all promethazine with codeine prescribing information, including Tris Pharma’s formulation. These warnings represent FDA’s formal determination that identified risks are serious enough to require the highest-visibility regulatory alert format.

Active Boxed Warnings (FDA, Updated 2025)

1. Addiction, Abuse, and Misuse
Codeine exposes patients and other users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Patient risk should be assessed prior to prescribing, with ongoing monitoring throughout treatment.

2. Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with codeine-containing medications, particularly during initiation of therapy and following dose increases.

3. Accidental Ingestion
Accidental pediatric ingestion of codeine-containing liquid medications can result in fatal opioid overdose. Secure, locked storage is not optional — it is a patient safety imperative.

4. Ultra-Rapid Metabolism of Codeine and Risk in CYP2D6 Ultra-Rapid Metabolizers
Life-threatening or fatal respiratory depression has occurred in children receiving codeine following tonsillectomy or adenoidectomy who were subsequently identified as CYP2D6 ultra-rapid metabolizers.

5. Risks from Concomitant Use with CNS Depressants
Concurrent use of opioids with benzodiazepines, alcohol, or other CNS depressants may produce profound sedation, respiratory depression, coma, and death.

Source: FDA DailyMed prescribing information — promethazine hydrochloride and codeine phosphate oral solution (2025)

Contraindications: Who Should Not Use This Medication

Absolute Contraindications

• Children under 12 years of age — FDA-prohibited due to established, unacceptable respiratory depression risk
• Postoperative pediatric patients following tonsillectomy or adenoidectomy — Documented fatal outcomes in CYP2D6 ultra-rapid metabolizing children
• Known hypersensitivity to promethazine, codeine, other opioids, or any phenothiazine-class compound
• Significant existing respiratory depression — Any patient with compromised baseline respiratory function where further suppression is clinically unacceptable
• Acute or severe bronchial asthma — In unmonitored settings or without immediately available resuscitative equipment and expertise
• Gastrointestinal obstruction — Including paralytic ileus or any condition producing functional bowel obstruction
• Concurrent MAOI use — Or within 14 days of MAOI discontinuation

High-Risk Populations Requiring Enhanced Clinical Caution

• Patients with COPD, sleep apnea, or any chronic respiratory compromise
• Elderly patients with baseline cognitive impairment, fall history, or frailty
• Patients with personal or first-degree family history of opioid use disorder
• Individuals with documented CYP2D6 ultra-rapid metabolizer genotype
• Pregnant patients — Neonatal Opioid Withdrawal Syndrome is a documented consequence
• Breastfeeding mothers — Contraindicated due to risk of fatal infant respiratory depression
• Patients on multiple CNS-active medications

When to Seek Emergency Care

Certain signs require immediate 911 activation — do not wait to observe whether symptoms improve.

Emergency Warning Signs

Call 911 immediately if any of the following occur after taking Tris Promethazine and Codeine Syrup:

• Slow, shallow, irregular, or stopped breathing
• Extreme or unrousable drowsiness — Person cannot be awakened
• Pinpoint pupils that do not respond to light
• Limpness or loss of muscle tone
• Choking, gurgling, or snoring sounds from the airway
• Blue, gray, or purple discoloration of lips, fingernails, or skin (cyanosis)
• Confusion, agitation, or sudden loss of consciousness
• Seizures
• Chest pain or irregular heartbeat

When in doubt, call 911. Opioid-related respiratory depression can progress from drowsiness to fatal apnea within minutes. Delayed emergency response is a primary factor in preventable overdose deaths.

Overdose Recognition and Emergency Response

Signs of Overdose

• Slow, shallow, or stopped breathing
• Extreme drowsiness or complete unresponsiveness
• Pinpoint (very small) pupils unresponsive to light
• Limp muscle tone throughout the body
• Choking or gurgling airway sounds
• Cyanosis — blue or purple discoloration of skin, lips, or fingernails
• Loss of consciousness

Emergency Response Protocol

1. Call 911 immediately — Do not delay to observe whether the person recovers spontaneously
2. Administer naloxone if available — Naloxone (Narcan) rapidly reverses opioid-mediated respiratory depression; it should be accessible in any household where opioid medications are stored. Naloxone is available without a prescription at most U.S. pharmacies.
3. Position the patient — Place an unconscious or semi-conscious person in the recovery position (on their side) to reduce aspiration risk
4. Stay with the patient until emergency medical services arrive
5. Provide complete medication information to emergency responders — drug name, dose taken, estimated time of ingestion, and any other substances consumed

Prevention Standard: The CDC recommends that prescribers co-prescribe naloxone for patients receiving opioid-containing medications and ensure that both patients and household members receive instruction on proper administration. Naloxone is increasingly available without a prescription through pharmacies, community harm-reduction programs, and state health department initiatives.

Key Statistics

• According to the CDC’s 2024 opioid surveillance report, opioids were involved in approximately 75% of all drug overdose deaths in the United States in recent reporting years
• CYP2D6 ultra-rapid metabolizer prevalence ranges from 1% to 29% depending on ethnic ancestry, according to pharmacogenetic data from the National Library of Medicine
• The FDA adverse event reporting system (FAERS) contains documented pediatric fatalities linked to codeine exposure through breast milk from CYP2D6 ultra-rapid metabolizing mothers
• Schedule V controlled substance prescriptions are tracked across all 50 U.S. states through Prescription Drug Monitoring Programs (PDMPs)

Patient Counseling Checklist

The following points represent essential patient education that should be confirmed at the point of prescribing and dispensing:

• ☐ Do not drink alcohol — including in any form — during the entire treatment course
• ☐ Do not drive or operate machinery while taking this medication
• ☐ Use only a calibrated oral dosing syringe — never a household spoon
• ☐ Store in a locked, secure location completely inaccessible to children and adolescents
• ☐ Never share this medication with another person under any circumstances
• ☐ Dispose of unused medication properly — use a DEA take-back location or FDA-approved disposal method
• ☐ Know the signs of overdose and keep naloxone accessible
• ☐ Inform all healthcare providers of this prescription before receiving any other medications
• ☐ Do not take more than prescribed — do not increase dose or frequency without direct prescriber guidance
• ☐ Notify your prescriber immediately if you experience difficulty breathing, extreme drowsiness, or any severe adverse effect

Frequently Asked Questions

What is Tris Promethazine and Codeine Syrup used for?

Tris Promethazine and Codeine Syrup is prescribed for the short-term relief of selected severe, non-productive coughs associated with upper respiratory illnesses when the expected clinical benefits outweigh the risks of opioid therapy. It is not indicated for productive cough, mild cough, or any use in children under 12.

What are the active ingredients in Tris Promethazine and Codeine Syrup?

Each standard 5 mL dose contains 6.25 mg of promethazine hydrochloride — a sedating first-generation phenothiazine antihistamine — and 10 mg of codeine phosphate, an opioid antitussive that acts centrally on mu-opioid receptors in the brainstem cough center.

What are the most common Tris promethazine codeine side effects?

Common side effects include drowsiness, dizziness, dry mouth, constipation, blurred vision, and nausea. Serious adverse effects — including respiratory depression, severe sedation, or loss of consciousness — require immediate emergency medical attention.

Can Tris Promethazine and Codeine Syrup be taken with alcohol?

No. Alcohol significantly amplifies CNS and respiratory depression produced by codeine-containing medications, creating risk of coma and death even at moderate intake levels. There is no safe threshold for concurrent alcohol use with this medication.

Why is Tris Promethazine and Codeine Syrup contraindicated in children under 12?

Children under 12 face an unacceptable risk of life-threatening respiratory depression from codeine, particularly those who are CYP2D6 ultra-rapid metabolizers and convert codeine to morphine at accelerated rates. The FDA has determined this risk is absolute and cannot be offset by any therapeutic benefit.

How long does Tris Promethazine and Codeine Syrup last?

Most patients experience symptom relief within 15 to 30 minutes. Cough suppression generally lasts 4 to 6 hours, while sedative effects from promethazine may continue for up to 12 hours depending on age, CYP2D6 metabolizer status, renal and hepatic function, and concurrent medications.

What medications interact with Tris Promethazine and Codeine Syrup?

Critical interactions include alcohol, benzodiazepines, other opioids, sedative-hypnotics, antipsychotics, muscle relaxants, MAO inhibitors, CYP2D6 inhibitors such as fluoxetine and paroxetine, and CYP3A4 inhibitors and inducers including ketoconazole and rifampin. Each interaction category carries distinct and potentially fatal clinical consequences.

Is Tris Promethazine and Codeine Syrup the same as generic promethazine with codeine?

FDA-approved generic formulations contain identical active ingredients at identical strengths and must meet bioequivalence standards. Differences in inactive ingredients — including flavoring, colorants, and preservatives — are clinically insignificant for most patients. Bioequivalent generics are therapeutically interchangeable with the Tris-branded product under standard prescribing conditions.

Can Tris Promethazine and Codeine Syrup cause a false positive drug test?

Yes. Codeine is metabolized to morphine and may produce a positive urine immunoassay result for opioids. Patients subject to workplace or clinical drug testing should disclose their prescription before providing a sample. Confirmatory GC-MS testing can differentiate prescribed codeine metabolites from illicit opioid use.

Can Tris Promethazine and Codeine Syrup be taken with food?

Yes. The medication may be taken with or without food. Taking it with food or water may reduce nausea in sensitive individuals without meaningfully altering drug absorption.

Can patients drive while taking Tris Promethazine and Codeine Syrup?

No. Promethazine produces substantial sedation lasting up to 12 hours — well beyond the antitussive window — and codeine independently impairs psychomotor performance. Patients must not drive, operate machinery, or perform any safety-sensitive task while taking this medication.

Can breastfeeding mothers take Tris Promethazine and Codeine Syrup?

No. This medication is contraindicated during breastfeeding. Codeine and its active morphine metabolite transfer through breast milk and can cause fatal respiratory depression in nursing infants, particularly those with CYP2D6 ultra-rapid metabolizer genotype.

Safe Storage and Disposal of Controlled Substances

Storage Requirements

• Store at controlled room temperature (20°C to 25°C / 68°F to 77°F)
• Keep in the original, child-resistant container
• Store in a locked, secure location completely inaccessible to children, adolescents, and individuals at risk for substance misuse
• Do not store in bathrooms, vehicles, or locations subject to temperature extremes or humidity fluctuation

Disposal

• Preferred method: Return unused medication to a DEA-authorized drug take-back location — pharmacy kiosks, law enforcement drop boxes, or scheduled community take-back events
• Acceptable household disposal: Mix with an undesirable substance such as coffee grounds, dirt, or kitty litter; seal in a bag; and discard in household trash — per FDA guidance when take-back is genuinely unavailable
• Do not flush unless the FDA flush list specifically includes the product and take-back access is not feasible
• Never share controlled substances with any other person under any circumstances — doing so is a federal crime

Conclusion

Tris Promethazine and Codeine Syrup occupies a clearly defined and carefully bounded clinical role: the short-term, supervised suppression of certain severe, non-productive coughs in appropriately selected patients. Its dual active ingredients — promethazine hydrochloride and codeine phosphate — provide complementary antihistaminic and opioid antitussive effects that deliver meaningful relief when alternatives have proven inadequate and when clinical benefits demonstrably outweigh the inherent risks of opioid therapy.

That risk-benefit calculus, however, is never trivial. The FDA’s Boxed Warnings for addiction, respiratory depression, and dangerous drug interactions reflect decades of documented harm associated with codeine-containing medications when used outside carefully controlled clinical parameters. The cultural misuse of promethazine with codeine purple syrup, the absolute pediatric contraindication, the pharmacogenetic complexity introduced by CYP2D6 variability, the breastfeeding prohibition, and the lethal potential of even a single interaction with alcohol or benzodiazepines all underscore why this medication demands the highest standard of prescriber vigilance, patient counseling, and institutional safeguarding.

For patients who require it, Tris Promethazine and Codeine Syrup — used precisely as prescribed, for the shortest clinically necessary duration, with full awareness of its interactions, contraindications, and warnings — represents a legitimate therapeutic tool with an established place in the pharmacological management of severe, non-productive cough. For everyone else, the risks are not hypothetical. They are well-documented, well-characterized, and entirely preventable through informed, disciplined prescribing and comprehensive patient education.

This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or individualized treatment guidance. Always consult a licensed healthcare professional before initiating, adjusting, or discontinuing any prescription medication.